Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

ns with several other parties regarding similar collaborations are ongoing. If successful, these collaborations could lead to these parties taking a licence to Silence delivery technologies.

Potential News Flow Events 2012-2014

In the near and medium term, the Directors believe there is the possibility of multiple potential news flow events from the existing product portfolio of programme deals, and opportunities within the RNAi technology platform, that could, dependent on success, act as value creation points for the business. The indicative dates are the Company's estimates, however no assurance can be given that the various events will be achieved by those dates, or indeed at all.

Internal Product Portfolio

Atu027 (treatment of solid tumours)

  • Completion of Phase I trial of Atu027 (July 2012)
  • Final Phase I results of Atu027 (third quarter of 2012)
  • Initiation of Phase Ib trial (end of 2012/early 2013)
  • Completion of Phase Ib trial (2014)

Atu111 (treatment of acute lung injury)

  • Completion of further proof-of-concept pre-clinical models (end 2012)

Partnered Product Portfolio

PF-'655 (diabetic macular oedema, glaucoma and age-related macular degeneration)

  • Completion of Phase IIb MATISSE study (2014)
  • Initiation of Phase IIa trial in glaucoma (trial start date not yet disclosed by Quark)

QPI-1002 (acute kidney injury 'AKI' and prevention of delayed graft function 'DGF')

  • Completion of Phase II trial in prevention of delayed graft function (second half of 2012)
  • Potential milestone payment upon Novartis' exercise of a license (2013)

Related Party Transaction

As part of the Fundraising, the Directors propose to issue 200,000,000 Subscription
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 AACC welcomed ... the 2015 AACC Annual Meeting & Clinical Lab ... July 26–30. The meeting showcased revolutionary advancements in ... ability of healthcare providers to diagnose patients quickly ... medical treatment. As of Wednesday, ...
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report on the ... state of the global Propanol market with a focus on the Chinese situation. Major ... Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... , July 30, 2015 Ascendis ... company that applies its innovative TransCon technology to ... top-line results from a six-month Phase 2 study ... TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal children ... "We are extremely pleased with the top-line results ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... CHICAGO, July 22 Research presented at the American ... monitoring cardiac transplant patients with the Urine NGAL assay on ... toxicity and adjust doses of cyclosporine drugs to prevent possible ... In a scientific poster presented at AACC today ...
... , , PHILADELPHIA, July 22 ... centralized ECG and eClinical technology, ePRO, and other services to the ... new Vice President of Project Management, Tammy Miller. Ms. Miller will ... In this new role, Ms. Miller will be responsible for the ...
... , , CHICAGO, July 22 Research ... that an assay developed by Abbott for simultaneous detection of both HIV ... in this study compared to HIV antibody-only assays. Earlier detection was ... , "The ability to use a blood test to ...
Cached Biology Technology:Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients 2ERT Appoints New Vice President of Project Management 2ERT Appoints New Vice President of Project Management 3Abbott HIV Test Demonstrates Earlier Disease Detection 2Abbott HIV Test Demonstrates Earlier Disease Detection 3
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
(Date:7/31/2015)... 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT ... method to advance crypto-currencies such as Bitcoin into the ... uniform way to manage all payments.  ...
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... to protect chickens, cats and humans against deadly flu pandemics, ... the Journal of General Virology . The vaccine protects ... be given to birds while they are still in their ... emergence of bird flu has posed a major challenge to ...
... St. Louis operates one of the largest and fastest ... in the western hemisphere. With the addition of a ... aroid species from Ecuador, the Garden,s permanent collection of ... of six million specimens. A herbarium is essentially ...
... counter-terrorism symposium tomorrow at NJIT from 8:30 a.m. - ... ways to secure schools, health and transportation facilities, protect ... and more. Presenters will include NJ State ... Homeland Security and Preparedness, U.S. Coast Guard and NJ ...
Cached Biology News:Bird flu vaccine protects people and pets 2Missouri Botanical Garden mounts milestone 6 millionth herbarium specimen 2Missouri Botanical Garden mounts milestone 6 millionth herbarium specimen 3
... These precision 5mm diameter, 7 inch long ... glass for compatibility with ground joints, valves, and ... NMR spectrometers running from 300 to 500MHz. They ... an I.D. of 4.20 + 0.013-0.000mm. These NMR ...
... for nucleic acid electrophoresis in agarose ... Preparation Quantity Equivalency: A final concentration ... stock solution can be made in ... Dye content ~ 75% Special ...
Preparation TW--Compatibility: Push-on end cap seals suitable up to 70 C only -Hybridization Tube for Model HB-1D -Comp Dim: 200 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-12...
... GenElute Gel Extraction Kit combines silica- binding technology ... column format. DNA fragments of interest are extracted ... the gel. The Gel Solubilization Solution can dissolve ... either TBE or TAE buffer. Extracted DNA fragments ...
Biology Products: